Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ligustrazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ligustrazine SCHEMBL28568980 | 0.95 | KDM4E (0.37) | KDM4EALDH1A1LMNASMN1; SMN2 | |
| Ligustrazine SCHEMBL27509607 | 0.94 | LMNA (0.41) | KDM4EALDH1A1LMNASMN1; SMN2NOS1 | |
| Ligustrazine SCHEMBL77624 | 0.94 | LMNA (0.41) | KDM4EALDH1A1LMNASMN1; SMN2NOS1 | |
| Ligustrazine SCHEMBL27734114 | 0.89 | ALDH1A1 (0.39) | KDM4EALDH1A1LMNASMN1; SMN2NOS1 | |
| Ligustrazine SCHEMBL583011 | 0.89 | KDM4E (0.39) | KDM4EALDH1A1LMNASMN1; SMN2NOS1 | |
| Ligustrazine SCHEMBL28208969 | 0.84 | KDM4E (0.37) | KDM4EALDH1A1LMNASMN1; SMN2 | |
| Ligustrazine SCHEMBL28588907 | 0.74 | TSHR (0.39) | KDM4EALDH1A1LMNASMN1; SMN2 | |
| Ligustrazine SCHEMBL19349460 | 0.74 | ALDH1A1 (0.46) | KDM4EALDH1A1LMNASMN1; SMN2 | |
| Ligustrazine SCHEMBL28172506 | 0.74 | LMNA (0.33) | KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12340091 | 0.74 | KDM4E (0.37) | KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 801 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-12220413-B2 | Magnetic nano-drug with double targeting VEGF-VEGFR, and preparation method and application thereof | THE THIRD CLINICAL MEDICAL COLLEGE, NANJING UNIVERSITY OF CHINESE MEDICINE (CN) | 2025-02-11 | — | — | US | claimed |
| CN-119371361-A | Preparation method and application of ligustrazine and salts thereof | 北京四环制药有限公司 | 2025-01-28 | — | — | CN | claimed |
| US-20250017920-A1 | MAGNETIC NANO-DRUG WITH DOUBLE TARGETING VEGF-VEGFR, AND PREPARATION METHOD AND APPLICATION THEREOF | THE THIRD CLINICAL MEDICAL COLLEGE, NANJING UNIVERSITY OF CHINESE MEDICINE (CN) | 2025-01-16 | — | — | US | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| CN-118879617-A | Animal model for ionizing radiation induced embryo damage and application thereof | 温州医科大学 | 2024-11-01 | — | — | CN | claimed |
| CN-118845812-A | Ligustrazine hydrochloride and icariin combined use and pharmaceutical composition for treating femoral head necrosis | 成都中医药大学 | 2024-10-29 | — | — | CN | claimed |
| CN-118576564-A | Double-drug-carrying liposome with alopecia preventing effect and preparation method and application thereof | 中国药科大学 | 2024-09-03 | — | — | CN | claimed |
| CN-118415972-A | Ligustrazine hydrochloride peppermint essential oil gel and preparation method thereof | 云南中医药大学 | 2024-08-02 | — | — | CN | claimed |
| CN-118203581-A | Ligustrazine, composition and application thereof | 暨南大学 | 2024-06-18 | — | — | CN | claimed |
| CN-1634403-A | Red sage root ligustrazine freeze dried injecta and preparation method thereof | SHIJIAZHUANG PHARM GROUP OUYI (CN) | 2005-07-06 | — | — | CN | claimed |
| CN-1634208-A | Injetio for treating coronary heart disease and its preparation process | SHANXI YABAO PHARMACEUTICAL GR (CN) | 2005-07-06 | — | — | CN | claimed |
| CN-1579399-A | Chuanxiongzine or chuanxiongzine salt drip pill and its preparing method | HONGYI SCIENCE TECHNOLOGY CO L (CN) | 2005-02-16 | — | — | CN | claimed |
| CN-1579495-A | Chinese medicinal preparation for treating cardiovascular diseases, and its preparation method and quality control method | YIBAI PHARMACEUTICAL CO LTD GU (CN) | 2005-02-16 | — | — | CN | claimed |
| CN-1555834-A | Medicinal composition containing salvia root effective component and ligusticum effecive component and its preparation | 广州安健实业发展有限公司 | 2004-12-22 | — | — | CN | claimed |
| CN-1509717-A | Skin penetrating paste containing ligustrazine free alkali and its preparation | 复旦大学 | 2004-07-07 | — | — | CN | claimed |
| CN-1457784-A | Method for producing xinnaoning injectin containing chuanxiong rhizome and red sage root extract | GUO DONGYU (CN) | 2003-11-26 | — | — | CN | claimed |
| CN-1432363-A | Transdermal Ligustrazine plaster and its prepn | UNIV FUDAN (CN) | 2003-07-30 | — | — | CN | claimed |
| CN-1425375-A | Ligustrazine hydrochloride freeze-dried preparation for injection and its preparing method | LI XIAOXIANG (CN) | 2003-06-25 | — | — | CN | claimed |
| CN-1262103-A | Chinese-medicinal compound extract for curing cerebrovascular diseases | LUYE PHARMACEUTICAL CO LTD SHA (CN) | 2000-08-09 | — | — | CN | claimed |